What is the global market size of Biopharmaceuticals Contract Manufacturing Market?

Biopharmaceuticals Contract Manufacturing Market size was valued at USD 17 billion in 2021 and is poised to grow from USD 17.88 billion in 2022 to USD 28.22 billion by 2030, growing at a CAGR of 5.2% in the forecast period (2023-2030).

Biopharmaceuticals Contract Manufacturing Market Size, Share, Growth Analysis, By Source(Mammalian, Non-mammalian), By Service(Process Development, Fill & Finish Operations, Packaging, others), By Product Type(Interferon, Monoclonal Antibodies, Protein, Vaccines), By Therapeutic Applications(Oncology, Cardiovascular Diseases, Others), By Region - Industry Forecast 2024-2031

Q: Who are the key vendors in the Global Biopharmaceuticals Contract Manufacturing Market?

Global biopharmaceuticals contract manufacturing market is consolidated in nature with the presence of several large market players operating across the globe. And, in terms of market share, top 5 players of the market are dominating the market including Boehringer Ingelheim, JSR Pharma, and Inno Biologics Sdn Bhd. These players are highly focusing on few business developing strategies including collaborations, mergers, new product innovations, and advance technology adoption to expand their geographical presence and product offerings. 'Boehringer Ingelheim GmbH', 'Catalent', 'Lonza Group AG', 'Thermo Fisher Scientific Inc.', 'Samsung BioLogics Co. Ltd.', 'Fujifilm Diosynth Biotechnologies', 'WuXi Biologics (Cayman) Inc.', 'AbbVie Inc.', 'AGC Biologics', 'Baxter BioPharma Solutions', 'Biocon Ltd.', 'Cytovance Biologics Inc.', 'Eurofins Scientific SE', 'Genscript Biotech Corporation', 'Grifols SA', 'Innovent Biologics (Suzhou) Co. Ltd.', 'JSR Corporation', 'KBI Biopharma Inc.', 'Merck KGaA', 'Novasep Holding SAS'.

Report ID: SQSG35H2019 | Region: Global | Published Date: April, 2024
Pages: 157 | Tables: 120 | Figures: 77

Biopharmaceuticals Contract Manufacturing Market News

In January 2022, INCOG BioPharma Services, an Indian-based contract development and manufacturing company, specialized in sterile injectables, announced the completion of its new manufacturing facility and global headquarters in Fisher.
In March 2021, JSR Pharma, announced the launch of its new corporate venture fund mainly focusing on various emerging biotech, engaging customers to their improved life sciences services portfolio. The new venture enable company to expand its revenue generation by offering innovated services to the global consumers.

Biopharmaceuticals Contract Manufacturing Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Biopharmaceuticals Contract Manufacturing Market size was valued at USD 17 billion in 2019 and is poised to grow from USD 17.88 billion in 2023 to USD 28.22 billion by 2031, growing at a CAGR of 5.2% in the forecast period (2024-2031).

biopharmaceuticals contract manufacturing market is consolidated in nature with the presence of several large market players operating across the globe. And, in terms of market share, top 5 players of the market are dominating the market including Boehringer Ingelheim, JSR Pharma, and Inno Biologics Sdn Bhd. These players are highly focusing on few business developing strategies including collaborations, mergers, new product innovations, and advance technology adoption to expand their geographical presence and product offerings. 'Boehringer Ingelheim GmbH', 'Catalent', 'Lonza Group AG', 'Thermo Fisher Scientific Inc.', 'Samsung BioLogics Co. Ltd.', 'Fujifilm Diosynth Biotechnologies', 'WuXi Biologics (Cayman) Inc.', 'AbbVie Inc.', 'AGC Biologics', 'Baxter BioPharma Solutions', 'Biocon Ltd.', 'Cytovance Biologics Inc.', 'Eurofins Scientific SE', 'Genscript Biotech Corporation', 'Grifols SA', 'Innovent Biologics (Suzhou) Co. Ltd.', 'JSR Corporation', 'KBI Biopharma Inc.', 'Merck KGaA', 'Novasep Holding SAS'

Increasing Demand for Biological Therapies

Introduction of AI Boosting Biopharmaceuticals Contract Manufacturing Market Growth

Globally, North America region dominated the biopharmaceuticals contract manufacturing with a holding of strong market share in 2021 due to the large number of biomanufacturing facilities in the United States. Additionally, interventions & conferences conducted in the North America for pertinent developing technologies and major issues in applications of biologics for the better treatment of several chronic disorders are likely to fuel the adoption of contract manufacturing services in the region over the coming years.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Biopharmaceuticals Contract Manufacturing Market News

Biopharmaceuticals Contract Manufacturing Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Biopharmaceuticals Contract Manufacturing Market?

Who are the key vendors in the Biopharmaceuticals Contract Manufacturing Market?

What is the key driver of Biopharmaceuticals Contract Manufacturing Market?

What is the key market trend for Biopharmaceuticals Contract Manufacturing Market?

Which region accounted for the largest share in Biopharmaceuticals Contract Manufacturing Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300